Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant pembrolizumab for MMRd uterine cancer (phase II efficacy study)
2024-516736-10-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in endometrial cancer (EC) and uterine cancer, sponsored by University Medical Center Groningen. Primary endpoint: Major pathological response rate. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
endometrial cancer (EC)uterine cancer
Beyond the preview
Go deeper on 2024-516736-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516736-10-00.